HC Wainwright Reaffirms Buy Rating for iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $21.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 173.44% from the company’s previous close.

Separately, Wedbush reiterated an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a research report on Thursday.

iTeos Therapeutics Trading Down 3.3 %

Shares of NASDAQ ITOS opened at $7.68 on Friday. The company has a 50 day simple moving average of $8.74 and a two-hundred day simple moving average of $12.95. The stock has a market cap of $280.58 million, a price-to-earnings ratio of -2.44 and a beta of 1.37. iTeos Therapeutics has a 12 month low of $7.44 and a 12 month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last posted its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.13. Analysts forecast that iTeos Therapeutics will post -3.46 EPS for the current year.

Insider Transactions at iTeos Therapeutics

In other iTeos Therapeutics news, CFO Matthew Gall bought 5,000 shares of iTeos Therapeutics stock in a transaction dated Tuesday, November 19th. The stock was acquired at an average cost of $7.73 per share, with a total value of $38,650.00. Following the purchase, the chief financial officer now directly owns 65,429 shares in the company, valued at $505,766.17. This represents a 8.27 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On iTeos Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC raised its position in iTeos Therapeutics by 212.5% during the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after acquiring an additional 1,700 shares during the period. Point72 DIFC Ltd purchased a new stake in shares of iTeos Therapeutics during the third quarter worth about $31,000. China Universal Asset Management Co. Ltd. raised its position in shares of iTeos Therapeutics by 60.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after purchasing an additional 2,646 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of iTeos Therapeutics during the 3rd quarter worth about $102,000. Finally, Quest Partners LLC lifted its stake in iTeos Therapeutics by 914.7% in the 3rd quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock valued at $113,000 after buying an additional 9,934 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.